The United States District Court for the District of Massachusetts entered a scheduling order in the ongoing Janssen v. Celltrion litigation concerning Celltrion’s Inflectra®, a biosimilar of Janssen’s Remicade® (infliximab), for the remainder of discovery, pre-trial activities, and trial.  The parties are ordered to reserve June 11, 2018 through June 29, 2018 for argument on pretrial issues including any motion for summary judgment, and July 30, 2018 through October 1, 2018 for final pre-trial activities and trial.

Stay tuned for the Big Molecule Watch for further updates.